证券研究报告 | 2025年08月26日 鱼跃医疗（002223.SZ） 优于大市 呼吸治疗业务企稳回升，血糖管理业务表现亮眼 公司 2025H1 收入及利润重回增长轨道。2025H1 公司实现营业收入 46.59 亿元，同比增长 8.2%；归母净利润 12.03 亿元，同比增长 7.4%。25Q2 单 季度公司实现营收 22.23 亿元，同比增长 7.1%；归母净利润 5.78 亿元，同 比增长 25.4%。受益于公司 CGM、家用呼吸机等产品的快速放量，公司营 收与利润端重回稳健增长状态。 销售费用率维持较高水平，利润端保持同比稳定。2025H1 公司销售费用率 17.4%（+3.1pp），主要因 CGM 等新品市场费用投入较多，导致销售人员 费用、电商平台费以及业务宣传费有较大提升；管理费用率 4.7%（-0.1pp）； 财务费用率-2.2%（+0.2pp）；研发费用率 6.3%，同比基本持平；公司目前 正处于市场投入扩张及产品迭代的加速期，预计销售费用与研发费用规模将 持续提升。公司 2025H1 毛利率 50.4%（+0.3pp），净利率 25.7%（-0.4pp）， 后续随着高毛利产品的放量，公司 ...

Summary of Conference Call Company and Industry - **Company**: Silicon Labs - **Industry**: Semiconductor and IoT (Internet of Things) Key Points and Arguments 1. **Market Recovery**: The company has observed a recovery in demand across various applications, including industrial, consumer, and medical sectors, despite macroeconomic uncertainties affecting visibility into future orders [6][7][8] 2. **Demand Trends**: Demand is described as reasonably healthy, with customers placing shorter-term orders (3-4 months) rather than long-term commitments, allowing flexibility amid macroeconomic changes [7][8] 3. **Segment Performance**: The industrial and commercial segments have shown better performance compared to the home and life segments, which are more sensitive to interest rates and real estate market conditions [9][10][12] 4. **Growth in Medical Sector**: The medical sector is identified as a growth area, largely driven by design wins, and is less affected by macroeconomic factors [13] 5. **Continuous Design Wins**: The company anticipates that Continuous Glucose Monitoring (CGM) applications will grow to represent 10% of revenue, with ongoing engagement with multiple customers in various stages of qualification [14][15][18] 6. **Electronic Shelf Labels (ESL)**: ESL is highlighted as a fast-growing application, with broader deployments expected in retail, particularly in North America and Europe [19][21][22] 7. **Market Size for ESL**: The total addressable market (TAM) for ESL is substantial, with potential for billions of units based on the number of SKUs and stores [22] 8. **Importance of Standards**: The adoption of standards like Matter and Thread is crucial for the smart home market, facilitating interoperability among devices [25][26] 9. **Series Two vs. Series Three**: Series Three products offer enhanced computing capabilities and security features compared to Series Two, with both series expected to coexist in the market [30][36] 10. **Design Win Pipeline**: The company has a $10 billion design win pipeline, which is expected to convert to approximately $2-2.5 billion in annual revenue over the next few years [38][39] 11. **Profitability and Investment Balance**: The company aims to balance investments in growth with a focus on improving profitability, targeting mid-teens operating margins while managing operating expenses [42][44] 12. **Gross Margin Outlook**: The long-term gross margin target is set at 56-58%, with current margins driven by product mix and scale, particularly in industrial applications [45][46] Other Important Content - **Geographic Deployment of ESL**: ESL is more prevalent in North America and Europe, with slower adoption in Asia Pacific [23][24] - **Customer Engagement**: The company has engaged with 60 potential customers in the CGM space, indicating confidence in securing additional design wins [18] - **Regulatory Environment**: Increasing government regulations regarding security standards are influencing product development, particularly for embedded microcontrollers [31][32]

Core Viewpoint - The company reported a decline in revenue and net profit for 2024, primarily due to high base effects from 2023 and adjustments in the respiratory therapy business, while showing growth in certain segments in Q1 2025 [1][2]. Financial Performance - For 2024, the company achieved revenue of 7.566 billion yuan (-5.09%), net profit attributable to shareholders of 1.806 billion yuan (-24.63%), and operating cash flow of 1.816 billion yuan (-14.61%) [1]. - In Q1 2025, the company reported revenue of 2.436 billion yuan (+9.18%), net profit of 625 million yuan (-5.26%), and operating cash flow of 658 million yuan (+2.64%) [1][2]. Business Segment Analysis - The respiratory therapy segment generated revenue of 2.597 billion yuan, with certain products experiencing declines due to high base effects, while home respiratory devices and nebulizers showed growth [2]. - The blood glucose management and POCT business achieved revenue of 1.03 billion yuan (+40.21%), with significant growth in CGM products [2]. - The home health measurement segment reported revenue of 1.564 billion yuan (-0.41%), with some products declining due to high base effects, while others like electronic blood pressure monitors saw double-digit growth [2]. - The clinical and rehabilitation business generated revenue of 2.093 billion yuan (+0.24%), with good growth trends in acupuncture needles and wheelchairs, but a decline in infection control products due to demand fluctuations [2]. - The emergency business reported revenue of 239 million yuan (+34.05%), with self-developed AED products achieving certification and further technical upgrades [2]. Strategic Initiatives - The company made a strategic investment of $27.21 million in Inogen, acquiring a 9.9% stake, to expand its market presence in Europe and the US, leveraging Inogen's established production bases and market share [3]. - The partnership with Inogen will focus on distribution cooperation for various respiratory products and aims to enhance product exports and collaborative R&D efforts [3]. Dividend Policy - In 2024, the company distributed a total dividend of 802 million yuan, representing 44.40% of net profit attributable to shareholders, reflecting a strong commitment to investor returns and long-term confidence [3]. Investment Outlook - The company is positioned as a leader in home medical devices, focusing on respiratory and oxygen therapy, blood glucose management, and infection control, with an improving product structure and brand advantages [4]. - Forecasts for net profit from 2025 to 2027 are adjusted to 2.341 billion yuan, 2.699 billion yuan, and 3.104 billion yuan, reflecting year-on-year growth of 29.63%, 15.29%, and 15.03% respectively [4].

Core Viewpoint - The company reported a decline in overall revenue and net profit for 2024, while specific segments like blood glucose management and emergency solutions showed significant growth [1][2]. Financial Performance - In 2024, the company achieved revenue of 7.566 billion yuan, a year-over-year decrease of 5.09%, and a net profit attributable to shareholders of 1.806 billion yuan, down 24.63% year-over-year [1]. - For Q1 2025, the company reported revenue of 2.436 billion yuan, an increase of 9.17% year-over-year, with a net profit of 625 million yuan, down 5.26% year-over-year [1]. Segment Performance - The blood glucose management and POCT solutions segment generated revenue of 1.03 billion yuan in 2024, growing by 40.20% year-over-year, driven by a significant increase in CGM and expansion of BGM customer base [2]. - The emergency solutions segment achieved revenue of 239 million yuan, up 34.05% year-over-year, benefiting from the certification and technological upgrades of the AED products [2]. - The respiratory therapy solutions segment saw revenue decline to 2.597 billion yuan, down 22.42% year-over-year, primarily due to fluctuations in public demand [2]. - The home health monitoring solutions segment reported revenue of 1.564 billion yuan, a slight decrease of 0.41% year-over-year, with some products experiencing growth despite high base effects [2]. - Clinical instruments and rehabilitation solutions generated revenue of 2.093 billion yuan, a marginal increase of 0.24% year-over-year, with certain product categories showing positive trends [2]. Profitability and Cost Management - The company achieved a gross margin of 50.14% in 2024, a decrease of 1.22 percentage points year-over-year, but is expected to stabilize and improve in Q1 2025 to 50.30% [3]. - The sales, management, and financial expense ratios for 2024 were 17.99%, 5.66%, and -3.12%, respectively, with a focus on optimizing costs and resource utilization [3]. International Expansion - The company’s overseas market revenue reached 949 million yuan in 2024, reflecting a year-over-year growth of 30.42%, supported by product registrations and localized team development [3]. Investment Outlook - The company is focused on the home medical device sector, particularly in respiratory and oxygen therapy, blood glucose management, and infection control, with rapid growth in international markets expected to enhance growth potential [4]. - Revenue projections for 2025-2027 are estimated at 8.548 billion yuan, 9.710 billion yuan, and 11.096 billion yuan, with corresponding year-over-year growth rates of 13.0%, 13.6%, and 14.3% [4].

Investment Rating - The report maintains a "Buy" rating for Yuyue Medical [2][10] Core Views - The company reported a better-than-expected Q1 2025 performance, with revenue of 2,436 million yuan, a year-on-year increase of 9.2%, and a net profit of 625 million yuan, a decrease of 5% [10] - The report highlights the company's product strength enhancement and accelerated overseas expansion as key growth drivers [10] - The company experienced a decline in revenue from COVID-related products in 2024, but other product lines showed growth, particularly in blood glucose management and emergency medical devices [10] Financial Data and Profit Forecast - Total revenue for 2024 is projected at 7,566 million yuan, with a year-on-year decline of 5.1%, while the forecast for 2025 is 8,730 million yuan, representing a growth of 15.4% [9][11] - The net profit for 2024 is expected to be 1,806 million yuan, down 24.6%, with a forecasted increase to 1,956 million yuan in 2025, reflecting an 8.3% growth [9][11] - The report provides a detailed breakdown of revenue growth across various product lines, indicating a strong performance in blood glucose management and emergency medical devices [10]

证券研究报告·公司点评报告·医疗器械 2024 年报及 2025 年一季报点评：25Q1 季报 高基数下好于预期，期待新品快速增长 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 7,972 | 7,566 | 8,760 | 10,134 | 11,711 | | 同比（%） | 12.25 | (5.09) | 15.78 | 15.69 | 15.56 | | 归母净利润（百万元） | 2,396 | 1,806 | 1,954 | 2,211 | 2,540 | | 同比（%） | 50.21 | (24.63) | 8.19 | 13.15 | 14.91 | | EPS-最新摊薄（元/股） | 2.39 | 1.80 | 1.95 | 2.21 | 2.53 | | P/E（现价&最新摊薄） | 13.90 | 18.44 | 17.04 | 15.06 | 13.11 | [Table_Tag] [ ...

Performance Overview - In 2024, the company reported total revenue of 7.566 billion yuan, a year-on-year decrease of 5% [1] - The net profit attributable to shareholders was 1.806 billion yuan, down 25% year-on-year [1] - The net profit excluding non-recurring items was 1.393 billion yuan, a decline of 24% year-on-year [1] - For Q4 2024, the company achieved revenue of 1.538 billion yuan, an increase of 18% year-on-year [1] - The net profit attributable to shareholders for Q4 2024 was 274 million yuan, up 34% year-on-year [1] - For Q1 2025, the company reported revenue of 2.436 billion yuan, a year-on-year increase of 9% [1] - The net profit attributable to shareholders for Q1 2025 was 625 million yuan, down 5% year-on-year [1] Operational Analysis - Revenue decline was influenced by high base effects, but blood glucose management and emergency business segments performed well [2] - The respiratory therapy solutions segment generated revenue of 2.597 billion yuan, a decrease of 22.42% year-on-year [2] - The blood glucose management and POCT solutions segment saw revenue of 1.03 billion yuan, an increase of 40.2% year-on-year, with CGM sales more than doubling [2] - The home health monitoring solutions segment achieved revenue of 1.564 billion yuan, a slight decrease of 0.41% year-on-year [2] - The clinical instruments and rehabilitation business segment reported revenue of 2.093 billion yuan, a marginal increase of 0.24% year-on-year [2] - The emergency business segment generated revenue of 239 million yuan, an increase of 34.05% year-on-year [2] Strategic Developments - The company accelerated its overseas market expansion, achieving foreign sales revenue of 949 million yuan, a year-on-year increase of 30.42% [3] - In January 2025, the company announced a strategic cooperation agreement with Inogen, focusing on international distribution, trademark licensing, joint R&D, and supply chain optimization [3] - Inogen is recognized for its strong international brand reputation and extensive sales channels in the respiratory field, which is expected to enhance the company's overseas market presence [3] Profit Forecast and Valuation - The company forecasts net profits attributable to shareholders of 2.025 billion yuan, 2.332 billion yuan, and 2.690 billion yuan for 2025, 2026, and 2027, respectively, representing year-on-year growth of 12%, 15%, and 15% [4] - The current price corresponds to a PE ratio of 16, 14, and 12 for the years 2025, 2026, and 2027 [4]

证券研究报告·公司点评报告·医疗器械 鱼跃医疗（002223） -16% -13% -10% -7% -4% -1% 2% 5% 8% 11% 14% 17% 2024/4/29 2024/8/28 2024/12/27 2025/4/27 鱼跃医疗 沪深300 2024 年报及 2025 年一季报点评：25Q1 季报 高基数下好于预期，期待新品快速增长 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 7,972 | 7,566 | 8,760 | 10,134 | 11,711 | | 同比（%） | 12.25 | (5.09) | 15.78 | 15.69 | 15.56 | | 归母净利润（百万元） | 2,396 | 1,806 | 1,954 | 2,211 | 2,540 | | 同比（%） | 50.21 | (24.63) | 8.19 | 13.15 | 14.91 | | EPS-最新摊薄 ...

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company's blood glucose business has shown a remarkable growth of 40%, with significant results from overseas expansion, leading to an income increase of over 30% [2] - In 2024, the company reported a revenue of 75.66 billion yuan, a year-on-year decrease of 5.09%, and a net profit attributable to shareholders of 18.06 billion yuan, down 24.63% year-on-year [2] - The company is expected to maintain stable growth in its core sectors, with a focus on enhancing its product matrix and brand influence, particularly in overseas markets [2] - The company is increasing its investment in technology and brand strength, which is anticipated to improve profitability in the long term [2] - Revenue forecasts for 2025-2027 are projected at 86.82 billion, 100.07 billion, and 115.20 billion yuan, with corresponding net profits of 21.11 billion, 24.94 billion, and 29.30 billion yuan, reflecting growth rates of 16.9%, 18.2%, and 17.5% respectively [2] Financial Summary - In 2024, the company achieved a gross margin of 50.14% and a net profit margin of 23.85% [2] - The projected earnings per share (EPS) for 2025, 2026, and 2027 are 2.11 yuan, 2.49 yuan, and 2.92 yuan respectively [3] - The company’s total revenue for 2023 was 79.72 billion yuan, with a year-on-year growth of 12.3% [3] - The net profit attributable to shareholders for 2023 was 2.396 billion yuan, reflecting a year-on-year increase of 50.2% [3]

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company's blood glucose business has shown a remarkable growth of 40%, with significant results from overseas expansion, leading to an overall revenue increase of over 30% [2] - In 2024, the company reported a revenue of 7.566 billion yuan, a year-on-year decrease of 5.09%, and a net profit attributable to shareholders of 1.806 billion yuan, down 24.63% year-on-year [2] - The company is expected to maintain stable growth in its core segments, with a focus on enhancing its product matrix and brand influence, particularly in overseas markets [2] Financial Performance Summary - In 2024, the company achieved total revenue of 75.66 billion yuan, with domestic revenue at 65.74 billion yuan (down 8.58% year-on-year) and overseas revenue at 9.49 billion yuan (up 30.42% year-on-year) [2] - The blood glucose management and POCT solutions business generated revenue of 10.30 billion yuan, reflecting a growth of 40.20% [2] - The company’s gross profit margin for 2024 was 50.14%, a decrease of 1.35 percentage points year-on-year, while the net profit margin was 23.85%, down 5.96 percentage points year-on-year [2] Revenue and Profit Forecast - The company is projected to achieve revenues of 86.82 billion yuan, 100.07 billion yuan, and 115.20 billion yuan for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 14.7%, 15.3%, and 15.1% [2] - The net profit attributable to shareholders is expected to be 2.111 billion yuan, 2.494 billion yuan, and 2.930 billion yuan for the same years, with growth rates of 16.9%, 18.2%, and 17.5% [2] - The price-to-earnings ratio (P/E) for 2025 is projected to be 16 times [2]